Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CTSH | P09668 | 1/20 | 0.36 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.35 |
| ▸ | MAX | P61244 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080546 | 0.86 | LMNA (0.40) | LMNAPIM3VCAM1MAPTCTSB | |
| SCHEMBL6591568 | 0.85 | CASP6 (0.39) | LMNAMAPTCTSBCTSHMEN1 | |
| SCHEMBL6591570 | 0.85 | CASP6 (0.39) | LMNAMAPTCTSBCTSHMEN1 | |
| SCHEMBL6080807 | 0.83 | LCK (0.43) | LMNAGAAMAPTNQO2MEN1 | |
| SCHEMBL6081116 | 0.80 | NQO2 (0.40) | GAAMAPTNQO2ERN1 | |
| SCHEMBL6079964 | 0.79 | SMN1; SMN2 (0.44) | LMNAMAPTAPPMYCMAX | |
| SCHEMBL6079981 | 0.78 | APP (0.49) | LMNAMAPTAPPCTSBERN1 | |
| SCHEMBL6080243 | 0.77 | ABCB1 (0.38) | LMNAPIM3VCAM1GAAMAPT | |
| SCHEMBL28429400 | 0.77 | APP (0.48) | LMNAGAAMAPTAPPMEN1 | |
| SCHEMBL2911144 | 0.75 | KMT2A (0.42) | LMNAGAAMAPTNQO2ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | LMNA 2027/4885PIM3 4001/4885VCAM1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.